Evaluation of Lifestyle Interventions to Treat Elevated Cardiometabolic Risk in Primary Care (E-LITE)

This study has been completed.
Sponsor:
Collaborators:
American Heart Association
Information provided by (Responsible Party):
Jun Ma, MD, PhD, Palo Alto Medical Foundation
ClinicalTrials.gov Identifier:
NCT00842426
First received: February 11, 2009
Last updated: September 11, 2012
Last verified: September 2012
  Purpose

The purpose of the E-LITE Study is to evaluate the feasibility and potential effectiveness of two lifestyle interventions in a community based primary care setting. The study aims to assess how changes in diet, exercise, and behavioral self-management affect weight and related risk factors for adults at risk for diabetes and cardiovascular disease.


Condition Intervention Phase
Obesity
Pre-diabetes
Metabolic Syndrome
Behavioral: Self-management program (SM)
Behavioral: Care management program (CM)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Health Services Research
Official Title: A Pilot of Customized Continuous Care Management of Obesity in Pre-Diabetics

Resource links provided by NLM:


Further study details as provided by Palo Alto Medical Foundation:

Primary Outcome Measures:
  • Body Mass Index [ Time Frame: Baseline, 3-, 6- and 15- month follow-up ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Metabolic syndrome criterion factors: waist circumference, BP, FBG, TG, HDL, TG/HDL [ Time Frame: Baseline, 6-, and 15-months ] [ Designated as safety issue: No ]
  • A1C, C-reactive protein [ Time Frame: Baseline and 15-months ] [ Designated as safety issue: No ]
  • Dietary Intake [ Time Frame: Baseline, 3-, 6-, and 15-months ] [ Designated as safety issue: No ]
  • Physical Activity [ Time Frame: Baseline, 3-, 6-, and 15-months ] [ Designated as safety issue: No ]
  • Generic and Obesity-specific Health Related Quality of Life [ Time Frame: Baseline, 3-, 6-, and 15-months ] [ Designated as safety issue: No ]
  • Patient and Physician Satisfaction [ Time Frame: Baseline, 3-, 6-, and 15-months ] [ Designated as safety issue: No ]

Enrollment: 241
Study Start Date: June 2009
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Usual Care
Usual Care
Experimental: Self-Management Program
Online Self-Management.
Behavioral: Self-management program (SM)

Participants will attend a group orientation where the study nutritionist will provide an overview of the self-management lifestyle intervention program. Participants will receive instructions on how to use HeartHubTM, the American Heart Association's patient portal for information, tools, resources about cardiovascular risk assessment, goal setting, action planning, and self-monitoring.

During the remainder of the 15-month intervention, participants will receive reminders on a regular basis to use the patient portal to assist in their ongoing self-management.

Other Name: Self-monitoring and online tracking
Experimental: Care Management Program
Care management lifestyle modification program with intensive intervention phase with exercise and nutrition specialist. Followed by a online self-management phase.
Behavioral: Care management program (CM)

In addition to participating in the activities described above, with the exception of the orientation session, participants in the Care Management Program will attend 12 weekly weight management classes during the initial 3 months. Classes will be co-led by a dietician and exercise specialist and will include a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by individual action-planning and goal-setting.

During the remainder of the 15-month intervention, participants will continue to monitor their body weight, caloric intake, physical activity, and other data according to their care plan. In addition, study interventionist will follow up with participants regularly, via secure messaging or by phone, to provide ongoing counseling and support.

Other Name: Intensive Lifestyle Program

Detailed Description:

In the United States, there is an epidemic of obesity and, as a result, an epidemic of diabetes. Obese individuals with pre-diabetes (defined as impaired fasting glucose or impaired glucose tolerance) are at high risk for progression to diabetes. A vast majority of these individuals also have an increased risk of cardiovascular disease because of concomitant risk factors, such as abdominal obesity, dyslipidemia, and elevated blood pressure. Intensive lifestyle interventions that focus on dietary change, physical activity, and behavior modification have demonstrated efficacy in achieving and maintaining clinically significant (>5%) weight loss in populations of patients with pre-diabetes. However, the effectiveness, cost-effectiveness, generalizability, and sustainability of such interventions in routine primary care settings remain unknown, and rigorous clinical research is needed.

The primary hypothesis for the E-LITE Study is that the CM intervention will reduce BMI more than the SM intervention, which in turn will reduce BMI more than usual care, over 15 months. Secondarily, we hypothesize that, compared with usual care, intervention participants will be associated with greater improvements in waist circumference, lipids, blood pressure, blood glucose, lifestyle behaviors, and psychosocial well-being. In addition, we will examine the durability of weight loss and behavioral change in the months after the initial 3-month intensive stage.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ethnicity: All ethnic groups;
  • Body mass index 25.0-39.9 kg/m2;
  • Fasting plasma glucose between 100 and 125 mg/dL;
  • Any two of the following: Waist circumference >40 inches in men, >35 inches in women (if in Asian American ≥ 35 inches in men; ≥31 inches in women); Triglycerides >150 mg/dL; High-density lipoprotein cholesterol (HDL-C) <40 mg/dL in men, <50 mg/dL in women; Systolic blood pressure >130 mm Hg or diastolic blood pressure >85 mm Hg.
  • Having a primary care physician (PCP) at the PAMF Los Altos Center;
  • Seen in primary or specialty care in the Palo Alto Region at least once in the preceding 24 months;
  • A PAMF patient for ≥ 12 months;
  • Able and willing to enroll and meet the requirements of the study.

Exclusion Criteria:

  • Inability to speak, read or understand English;
  • No regular access to a computer with Internet and email capabilities;
  • Triglycerides >400 mg/dL;
  • Systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg;
  • Initiation or change of drug therapy for elevated blood pressure or abnormal lipid levels within the past 3 months
  • Having a medical (e.g., celiac disease) or social condition (e.g., religious beliefs) that precludes dietary changes;
  • Having a medical or physical condition that make moderate intensity physical activity (like a brisk walk) difficult or unsafe;
  • Use of weight-loss medications in the past 3 months;
  • Regular use (> 5 days/month) of medications that affect appetite or weight (e.g., oral corticosteroids, insulin, certain oral hypoglycemics, certain antidepressants, etc.);
  • Currently enrolled in a lifestyle intervention program at PAMF or elsewhere;
  • Planning to undergo a bariatric surgery during the study period;
  • Diagnosis of Type 1 or Type 2 diabetes mellitus;
  • Significant medical co-morbidities, including uncontrolled metabolic disorders (e.g., thyroid, renal, liver), heart disease, stroke, and ongoing substance abuse;
  • Renal insufficiency (i.e., GFR < 60 mL/min/1.73m2)
  • Diagnosis of psychiatric disorders that would limit adequate informed consent or ability to comply with study protocol;
  • Diagnosis of cancer (other than non-melanoma skin cancer) that was active or treated with radiation or chemotherapy within the past 2 years;
  • Diagnosis of a terminal illness and/or in hospice care;
  • Pregnant, lactating or planning to become pregnant during the study period;
  • Already enrolled or planning to enroll in a research study that would limit full participation in this study or confound the observation and interpretation of the study's findings;
  • Family/household member of another study participant or of a study staff member;
  • No longer a PAMF patient or planning to transfer care outside of PAMF during the study period;
  • Planning to move out of the area during the study period;
  • PCP determination that the study is inappropriate or unsafe for the patient;
  • Investigator discretion for clinical safety or protocol adherence reasons.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00842426

Locations
United States, California
Palo Alto Medical Foundation, Los Altos Center
Palo Alto, California, United States, 94022
Sponsors and Collaborators
Palo Alto Medical Foundation
American Heart Association
Investigators
Principal Investigator: Jun Ma, M.D., Ph.D. Palo Alto Medical Foundation
  More Information

No publications provided by Palo Alto Medical Foundation

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jun Ma, MD, PhD, Associate Investigator, Palo Alto Medical Foundation
ClinicalTrials.gov Identifier: NCT00842426     History of Changes
Other Study ID Numbers: R34 DK080878
Study First Received: February 11, 2009
Last Updated: September 11, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Palo Alto Medical Foundation:
Diabetes
Cardiovascular disease
Metabolic syndrome
Cardiometabolic

Additional relevant MeSH terms:
Diabetes Mellitus
Obesity
Glucose Intolerance
Prediabetic State
Metabolic Syndrome X
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Hyperglycemia
Insulin Resistance
Hyperinsulinism

ClinicalTrials.gov processed this record on April 17, 2014